First is that there were significant baseline differences in gender, BMI and ALF scores between the groups at baseline.
We examined for the presence of confounders in patients with and without therapeutic drug levels, and found no statistically significant baseline differences in gender, steroid use, duration of voriconazole therapy, obesity (defined as weight ≥ 90 kg), duration of neutropenia ≥ 10 days, presence of graft-versus-host-disease, or use of combination antifungals.
A computer-assisted, least square method was used in random assignment to ensure that there was no baseline difference in gender, age, BMI, HbA1c, or duration of SU use between the two groups.
A summary of the patients' baseline characteristics is presented in table 3, and no significant baseline differences in age, gender and diagnosis between the groups were found.
This suggests that male students may have more potential to improve attention performance after training, but also that baseline differences in mixed-gender groups should be controlled for.
Student's t-tests were used to determine any baseline differences in the groups for age, gender, number of previous trials of SSRI's, severity of symptoms in relation to OCD, depressive symptoms, and CGI-S.
Additional nested variables were added to the analysis in order to adjust for any baseline differences in the distribution of certain variables (e.g. gender) between the groups.
Model 1 establishes baseline differences in remittance-sending among the historical cohorts, net of period, age, marital status, and gender.
To correct for baseline differences in demographics, the data on PA was implemented in the Chronic Disease Model per age subgroup 50-64 yearss, >64 years) and gender subgroup.
Baseline between-group differences in gender and education level were assessed with the Chi2 test, and age was evaluated with a one-way ANOVA.
Baseline between-group differences in gender and education level were assessed with the Chi test and age was evaluated with a one-way ANOVA.
